Cardlytics (NASDAQ:CDLX) posted its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.23, Briefing.com reports. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 64.83%. The firm had revenue of $48.73 million for the quarter, compared to analysts’ expectations of $43.77 million. During the same quarter last year, the firm earned ($0.21) EPS. The company’s quarterly revenue was up 37.0% compared to the same quarter last year. Cardlytics updated its FY 2019 guidance to EPS and its Q3 2019 guidance to EPS.
Shares of Cardlytics stock traded down $0.04 during mid-day trading on Friday, hitting $32.90. 477,591 shares of the stock were exchanged, compared to its average volume of 286,852. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $743.44 million, a P/E ratio of -15.37 and a beta of 1.76. The firm’s 50-day moving average is $27.77. Cardlytics has a 12 month low of $9.80 and a 12 month high of $34.30.
In related news, CEO Scott D. Grimes sold 6,000 shares of Cardlytics stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $30.99, for a total value of $185,940.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Scott D. Grimes sold 4,000 shares of Cardlytics stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $23.76, for a total transaction of $95,040.00. The disclosure for this sale can be found here. Insiders sold a total of 506,715 shares of company stock worth $13,244,948 in the last ninety days. 21.90% of the stock is currently owned by insiders.
Several equities analysts have commented on CDLX shares. ValuEngine cut shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. Bank of America reissued a “buy” rating and set a $32.00 target price (up previously from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. William Blair started coverage on shares of Cardlytics in a research report on Monday, July 1st. They set an “outperform” rating on the stock. SunTrust Banks lifted their target price on shares of Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Raymond James lifted their target price on shares of Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $30.71.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Featured Article: What is the Dividend Aristocrat Index?
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.